Waldenström Macroglobulinemia (WM)

Waldenström macroglobulinemia is a rare type of slow-growing blood cancer. It starts in B-lymphocytes (a type of white blood cell) inside the bone marrow. These B-cells become abnormal and behave like a mix between a lymphoma cell and a plasma cell. They make large amounts of a single antibody called IgM (immunoglobulin M). Because IgM is a big, heavy protein, too much of it can make the blood thick and sticky (this is called hyperviscosity). Thick blood flows more slowly and may cause headaches, nosebleeds, vision problems, or confusion. The cancer cells can also crowd out healthy marrow, causing anemia (tiredness, shortness of breath), low platelets (easy bruising or bleeding), and low white cells (more infections).

Waldenström macroglobulinemia (WM) is a cancer of white blood cells called B cells. In WM, these B cells partly turn into plasma-like cells and build up in the bone marrow. These abnormal cells make a single type of antibody called IgM in very large amounts. Too many of these cells in the marrow can crowd out normal blood-forming cells and cause anemia (low red cells), low platelets, or low white cells. Too much IgM can also make the blood thick (this is called hyperviscosity), which can lead to problems like blurred vision, headaches, nosebleeds, and confusion. Doctors classify WM as a lymphoplasmacytic lymphoma that always has a monoclonal IgM protein in the blood. That is the key idea: lymphoplasmacytic lymphoma + IgM spike = WM. PMCWaldenstrom’s FoundationScienceDirect

At the DNA level, most people with WM have a change (mutation) in a signaling gene called MYD88 (most often L265P). A smaller group also has mutations in CXCR4. These mutations help the cancer cells stay alive and divide. Testing for these mutations helps doctors confirm the diagnosis and sometimes guides treatment choices. PMCAACR Journals

---

Types

There is no single “official” list of types like you might see for some other cancers, but doctors commonly describe WM in the following practical subgroups to guide monitoring and care:

1. Asymptomatic (smoldering) WM
   You have the typical WM lab pattern (bone-marrow LPL cells plus an IgM spike), but no symptoms and no organ damage. Many people can be safely observed without immediate treatment. PubMed

2. Symptomatic (active) WM
   WM is causing anemia, thick blood (hyperviscosity), enlarged lymph nodes or spleen, nerve damage (neuropathy), kidney, heart, or other organ problems, or systemic symptoms (fever, night sweats, weight loss). Treatment is recommended. PubMed

3. IgM-related disorders linked to WM cells
   Sometimes the IgM or the LPL cells cause special problems:
   • Hyperviscosity syndrome (thick blood causing neurologic and eye symptoms)
   • Cold agglutinin disease (IgM sticks to red cells in the cold and causes hemolysis)
   • Cryoglobulinemia (proteins that precipitate in the cold, leading to skin, nerve, or kidney issues)
   • Anti-MAG neuropathy (IgM damages myelin on peripheral nerves, causing numbness/tingling and imbalance)
   These problems are common reasons people need therapy. NCBIWaldenstrom’s Foundation

4. Central nervous system (CNS) involvement — Bing–Neel syndrome
   Rarely, WM cells enter the brain or spinal cord. People can have headaches, cognitive changes, balance issues, or vision problems. Diagnosis uses MRI and CSF testing. Treatment differs from standard WM therapy. PMCHaematologica

5. Genetic profile–based groups
   • MYD88-mutated / CXCR4-wild type (most common)
   • MYD88-mutated / CXCR4-mutated (about a third)
   • MYD88-wild type (uncommon; may behave differently and is important diagnostically) PMC+1

---

Causes and contributing risk factors

Important context: For most people, the exact cause of WM is unknown. Researchers have identified risk factors and contributors, but having a risk factor does not mean you will get WM. Below are factors linked to higher chances of WM or closely related conditions:

1. Somatic MYD88 L265P mutation – a common driver change that helps B-cells survive. It is acquired in the tumor cells; you are not born with it. PMC

2. CXCR4 mutations – occur in a sizeable minority; can affect how cells respond to signals and may influence symptoms. PMC

3. Age – WM is much more common in older adults (average diagnosis ~70 years). LLS

4. Male sex – men are affected more often than women. American Cancer Society

5. Race/ancestry – higher rates in people of Northern European ancestry; lower in some other groups. PMC

6. Family history – having close relatives with WM or other B-cell cancers raises risk modestly. PMC

7. IgM MGUS (a precursor condition) – some people with IgM monoclonal gammopathy progress to WM over time. Haematologica

8. Chronic immune stimulation – long-standing immune activation has been linked to LPL/WM in epidemiologic studies. Oxford Academic

9. Certain autoimmune diseases – some data suggest associations (for example, Sjögren’s, thyroiditis), but these do not prove causation. Oxford Academic

10. Hepatitis C virus (HCV) – evidence is mixed; some studies suggest an association, others do not. If present, HCV can also cause cryoglobulinemia that overlaps with WM issues. PMC+1Waldenstrom’s

11. HIV or immune deficiency – immune dysregulation may contribute; overall risk is still low at the individual level. American Cancer Society

12. Occupational exposures: pesticides – reported in pooled studies of lymphomas including LPL/WM. Oxford Academic

13. Occupational exposures: organic solvents – e.g., benzene-like solvents; signals seen in case-control work. ResearchGate

14. Wood dust and farming – associations noted in epidemiologic projects of LPL/WM. Oxford Academic

15. Possible genetic susceptibility regions – e.g., specific chromosome loci and familial clustering suggest inherited susceptibility, even though the tumor mutations are acquired. PMC

16. Epigenetic changes with aging – aging B-cells accumulate changes that may favor clonal growth (conceptual contributor across many lymphomas). PMC

17. Prior IgM-related neuropathy – in some, prolonged IgM activity (anti-MAG) reflects the same clone that later meets criteria for WM. ScienceDirect

18. Long-standing infections causing cryoglobulinemia – can coexist with or unmask IgM clones that meet WM criteria. PMC

19. Male hormonal milieu / lifestyle correlates – male predominance exists, but specific hormone or lifestyle causes remain unproven; listed here to explain the observed pattern. PMC

20. Random chance – as with many cancers, chance errors in dividing cells can accumulate over life; many people have no identifiable risk factor. PMC

---

Common signs and symptoms

Not everyone has all symptoms. Some people feel well and are diagnosed from routine blood tests. When symptoms occur, they often relate to anemia, thick blood (hyperviscosity), nerve problems, bleeding, or organ enlargement:

1. Tiredness and weakness – usually from anemia when the marrow is crowded by WM cells. American Cancer Society

2. Shortness of breath with effort – another effect of anemia and thick blood. American Cancer Society

3. Unintentional weight loss – a general “B symptom” of lymphomas. American Cancer Society

4. Fever and night sweats – systemic inflammation from lymphoma activity. American Cancer Society

5. Easy bruising or nosebleeds – from low platelets or interference of IgM with clotting. American Cancer Society

6. Headache, dizziness, ringing in ears, confusion – classic hyperviscosity symptoms due to sluggish blood flow. Emergency treatment (plasmapheresis) may be needed if severe. NCBI

7. Blurred or double vision – hyperviscosity damages tiny retinal vessels; eye exam may show “sausage-link” veins or retinal hemorrhages. NCBI

8. Numbness, tingling, imbalance – peripheral neuropathy, often related to IgM antibodies attacking myelin (e.g., anti-MAG). Waldenstrom’s Foundation

9. Cold-triggered color change or pain in fingers/toes – cryoglobulins or cold agglutinins can impair circulation in the cold. PMC

10. Enlarged lymph nodes – due to lymphoma tissue outside the marrow. PMC

11. Fullness under left ribs or early satiety – from enlarged spleen; liver can also enlarge. PMC

12. Recurrent infections – abnormal antibodies don’t protect well, and normal antibodies may be low. PMC

13. Skin changes (purpura, livedo, ulcers) – from cryoglobulinemia, hyperviscosity, or low platelets. PMC

14. Bone pain is uncommon – lytic bone lesions typical of myeloma are usually absent in WM, which helps tell them apart. LLS

15. Neurologic changes from CNS involvement (rare) – in Bing–Neel syndrome: cognitive changes, gait issues, cranial nerve symptoms. PMC

---

Diagnostic tests

Doctors combine your story, exam, labs, marrow testing, and imaging to make the diagnosis. The essentials are: finding lymphoplasmacytic lymphoma in the bone marrow and confirming a monoclonal IgM in the blood; MYD88 testing is strongly recommended. Below are 20 tests explained in simple words. Waldenstrom’s FoundationLLS

A) Physical examination

1. General exam with vital signs and performance status
   Checks fever, weight loss, heart rate, blood pressure, and how active you can be. This helps stage urgency and safety for treatment decisions. PMC

2. Lymph-node, liver, and spleen exam
   Doctors feel the neck, armpits, groin, abdomen for enlarged nodes or organs, which suggest disease beyond the marrow. PMC

3. Bedside eye (funduscopic) exam
   Using an ophthalmoscope to look for “sausage-link” veins, hemorrhages, or swelling of the optic disc—signs of hyperviscosity that need urgent attention. NCBI

B) Manual (bedside) tests

4. Snellen visual-acuity chart
   A quick way to document blurry vision from hyperviscosity or retinal changes and to monitor improvement after treatment. NCBI

5. Orthostatic (lying-to-standing) blood pressure
   Screens for dizziness related to thick blood or anemia and helps detect volume issues before therapies like plasmapheresis. NCBI

6. 10-g monofilament and 128-Hz tuning-fork vibration tests
   Simple bedside checks for large-fiber neuropathy in the feet and hands from IgM-related nerve damage. Waldenstrom’s Foundation

C) Laboratory & pathological tests

7. Complete blood count (CBC) with differential + peripheral smear
   Looks for anemia, low platelets, or abnormal lymphoplasmacytic cells; the smear helps spot rouleaux and other red-cell changes. PMC

8. Serum protein electrophoresis (SPEP) with immunofixation (IFE)
   Identifies and confirms a monoclonal IgM (“M-protein”). This is a core test for WM. PMC

9. Quantitative immunoglobulins (IgM, IgG, IgA)
   Measures exact IgM level and checks if protective IgG/IgA are low, which can cause infections. PMC

10. Serum viscosity (SV)
    Measures how thick the blood is; guides the need for urgent plasmapheresis when symptoms of hyperviscosity appear. Waldenstrom’s Foundation

11. Serum free light chains ± 24-hour urine IFE/UPEP
    Looks for extra light chains that may contribute to kidney or amyloid issues and helps in the differential with myeloma. PMC

12. β2-microglobulin and LDH
    “Tumor-burden” and cell-turnover markers that aid risk stratification and prognosis. Waldenstrom’s Foundation

13. Bone marrow aspirate and core biopsy with morphology/IHC
    This is diagnostic: shows lymphoplasmacytic lymphoma in the marrow. Pathologists use stains for B-cell markers (CD19, CD20, surface IgM, light-chain restriction). PMC

14. Flow cytometry (marrow and/or blood)
    Confirms the immunophenotype typical of WM and helps distinguish WM from look-alikes (e.g., marginal zone lymphoma, CLL, IgM myeloma). PMC

15. MYD88 L265P mutation testing (AS-PCR or ddPCR)
    Strongly recommended in guidelines; positive in ~90% of WM and supports the diagnosis. LLSPMC

16. CXCR4 mutation testing
    Present in ~30%; may correlate with certain symptoms and sometimes influences drug responses. PMC

D) Electrodiagnostic studies

17. Nerve conduction studies (NCS)
    Detect demyelinating neuropathy typical of anti-MAG–related nerve damage (slowed conduction, prolonged distal latencies). PMC+1

18. Electromyography (EMG)
    Complements NCS to characterize neuropathy pattern and to rule out other causes of weakness. PMC

E) Imaging tests

19. CT scan of chest/abdomen/pelvis
    Looks for lymph-node enlargement, liver or spleen enlargement, and guides staging and treatment planning. PMC

20. MRI of brain/spine (if neurological “red flags”)
    Essential when Bing–Neel syndrome is suspected; often paired with CSF analysis to prove CNS involvement. PMC

Non-Pharmacological Treatments (Therapies and Other Measures)

These are “no-pill” or “procedure and lifestyle” strategies. They support medicines, improve safety, and reduce symptoms. Each item has a description, purpose, and mechanism (how it helps).

1. Therapeutic Plasma Exchange (Plasmapheresis)
   Description: A machine removes some of your plasma (the liquid part of blood) and replaces it with a safe fluid.
   Purpose: Quickly lowers very high IgM to treat hyperviscosity.
   Mechanism: IgM sits in plasma; removing plasma immediately reduces its level and thins the blood.

2. Careful Watch-and-Wait (Active Surveillance)
   Description: Regular checkups without immediate drugs when symptoms are mild or absent.
   Purpose: Avoids side effects until treatment is necessary.
   Mechanism: WM is often slow; close monitoring (labs, exams) keeps you safe.

3. Vaccinations (non-live)
   Description: Flu shot, pneumococcal, COVID-19 boosters, and other guideline-recommended, non-live vaccines.
   Purpose: Lower risk of pneumonia and severe viral illness.
   Mechanism: Builds immune memory when immunity may be weaker from WM or its therapies.

4. Infection Prevention (Hygiene + Exposure Control)
   Description: Hand hygiene, mask in crowded indoor spaces during outbreaks, food safety.
   Purpose: Cut infection risk when white cells or antibodies are low.
   Mechanism: Reduces contact with germs at the source.

5. Physical Activity Program
   Description: Gentle aerobic and resistance exercise 3–5 days/week, personalized to energy level.
   Purpose: Improves fatigue, bone health, mood, and heart fitness.
   Mechanism: Boosts oxygen delivery, muscle strength, and anti-inflammatory pathways.

6. Nutrition Counseling
   Description: Balanced diet rich in proteins, fruits/vegetables, whole grains; manage weight.
   Purpose: Maintain energy, prevent muscle loss, support immunity and healing.
   Mechanism: Supplies macro- and micro-nutrients needed for marrow and immune function.

7. Neuropathy Safety Plan
   Description: Foot care, protective footwear, home fall-proofing, physical therapy if needed.
   Purpose: Prevent injuries when tingling or numbness occurs (can happen with disease or some drugs).
   Mechanism: Reduces pressure, improves balance and nerve health.

8. Fatigue Management
   Description: Sleep hygiene, pacing of activities, rest breaks, mind-body therapy.
   Purpose: Reduce cancer-related tiredness.
   Mechanism: Supports circadian rhythm, energy budgeting, and stress reduction.

9. Psychological Support / Counseling
   Description: Counseling, peer support groups, cognitive-behavioral therapy.
   Purpose: Manage anxiety or low mood that can accompany chronic illness.
   Mechanism: Builds coping skills, social connection, and resilience.

10. Work and Daily-Life Adjustments
    Description: Flexible schedules, sitting tasks, heat/cold control, adequate lighting.
    Purpose: Match daily tasks to energy level and symptoms (e.g., dizziness).
    Mechanism: Lowers physiological stress and injury risk.

11. Bone Health Plan
    Description: Calcium, vitamin D (as advised), weight-bearing exercise; DEXA scans when indicated.
    Purpose: Protect against bone loss, especially with steroids or inactivity.
    Mechanism: Supplies bone minerals and mechanical stimulus to keep bones strong.

12. Bleeding-Risk Reduction
    Description: Electric razor, soft toothbrush, avoid high-risk contact sports.
    Purpose: Lower bleeding risk if platelets are low or on drugs that raise bleeding risk.
    Mechanism: Minimizes trauma to skin and mucosa.

13. Cold-Exposure Precautions
    Description: Warm clothing, avoid very cold drinks/environments if you have cryoglobulins or cold agglutinins.
    Purpose: Prevent circulation problems triggered by cold.
    Mechanism: Heat keeps proteins from clumping and preserves blood flow.

14. Vision Care
    Description: Prompt eye checks when blurry vision, floaters, or headaches occur.
    Purpose: Detect retinal changes from hyperviscosity early.
    Mechanism: Eye exams can show vessel changes before damage progresses.

15. Medication Review (Polypharmacy Check)
    Description: Regular pharmacist/clinician review of all prescriptions and supplements.
    Purpose: Avoid drug interactions that increase bleeding, infection, or neuropathy risk.
    Mechanism: Optimizes safe combinations and dosing.

16. Sun and Skin Care
    Description: Sunscreen, skin checks, moisturizers.
    Purpose: Protect skin if on therapies that make you sun-sensitive or immunosuppressed.
    Mechanism: Reduces burns, infections, and skin breakdown.

17. Travel Precautions
    Description: Carry medical summary, hydrate well, stretch legs during flights; travel insurance.
    Purpose: Manage clot risk, dehydration, and access to care.
    Mechanism: Keeps blood moving and ensures quick help if needed.

18. Advance Care Planning (Early Conversations)
    Description: Discuss preferences for care if health changes.
    Purpose: Ensure care matches your goals and values.
    Mechanism: Clear documentation guides the team in any scenario.

19. Caregiver and Family Education
    Description: Teach family warning signs (sudden headache, vision changes, heavy bleeding, fever).
    Purpose: Faster response when symptoms start.
    Mechanism: Informed helpers shorten time to treatment.

20. Financial and Navigation Support
    Description: Social worker help for coverage, transport, lodging near treatment centers.
    Purpose: Reduce stress and improve adherence to care.
    Mechanism: Removes practical barriers to getting treatment on time.

---

Drug Treatments

Doses below are typical starting or commonly used adult regimens. Your oncologist will individualize dosing based on age, kidney/liver function, drug combinations, and side effects.

1. Zanubrutinib (BTK inhibitor)
   Dose/Time: 160 mg by mouth twice daily or 320 mg once daily, continuous.
   Purpose: First-line or relapsed WM; often preferred due to efficacy and heart-rhythm safety profile vs older BTK drugs.
   Mechanism: Blocks BTK, a key signal that WM cells use to survive.
   Side effects: Low blood counts, bruising/bleeding risk, diarrhea, rash, infections; rare heart rhythm issues.

2. Ibrutinib (BTK inhibitor)
   Dose/Time: 420 mg by mouth once daily, continuous.
   Purpose: Active WM, including relapsed disease.
   Mechanism: BTK blockade reduces growth signals in malignant B-cells.
   Side effects: Diarrhea, bleeding risk, high blood pressure, atrial fibrillation, infections.

3. Rituximab (anti-CD20 monoclonal antibody)
   Dose/Time: 375 mg/m² IV weekly × 4, or in cycles with combinations.
   Purpose: Backbone of many WM regimens; targets CD20 on B-cells.
   Mechanism: Immune system destroys rituximab-coated B-cells.
   Side effects: Infusion reactions, infections, rare hepatitis B reactivation; may cause “IgM flare” (temporary IgM rise)—sometimes plasmapheresis is done before/after.

4. Bendamustine + Rituximab (BR)
   Dose/Time: Bendamustine 90 mg/m² IV days 1–2 + rituximab day 1, q28d × 4–6 cycles (doses vary).
   Purpose: Highly effective first-line option.
   Mechanism: Bendamustine damages DNA; rituximab targets B-cells.
   Side effects: Low blood counts, infections, nausea, fatigue; tumor lysis monitoring in heavy disease.

5. DRC (Dexamethasone-Rituximab-Cyclophosphamide)
   Dose/Time (example): Dexamethasone 20 mg day 1; rituximab 375 mg/m² day 1; cyclophosphamide 100 mg orally twice daily days 1–5, q21d × 6.
   Purpose: Well-tolerated regimen for many patients.
   Mechanism: Steroid + alkylator + anti-CD20 work together to kill WM cells.
   Side effects: Low counts, infections, fatigue; cyclophosphamide can cause nausea; steroid effects (sleep, mood, sugar).

6. Bortezomib ± Dexamethasone ± Rituximab (BDR)
   Dose/Time (example): Bortezomib 1.3 mg/m² SC days 1, 8, 15 q28d (weekly schedules reduce neuropathy).
   Purpose: Useful when rapid IgM drop is needed; effective in neuropathy-prone regimens if given weekly and subcutaneously.
   Mechanism: Proteasome inhibition causes toxic protein buildup in cancer cells.
   Side effects: Peripheral neuropathy, low counts, shingles reactivation (antiviral prophylaxis often used), GI upset.

7. Ixazomib + Rituximab + Dexamethasone
   Dose/Time (example): Ixazomib 4 mg PO days 1, 8, 15 q28d × 6; with rituximab and weekly dexamethasone per protocol.
   Purpose: All-oral proteasome inhibitor–based option.
   Mechanism: Similar to bortezomib, but oral.
   Side effects: Low counts, rash, GI symptoms, neuropathy (usually milder than bortezomib).

8. Venetoclax (BCL-2 inhibitor; selected relapsed settings)
   Dose/Time: Oral daily with gradual ramp-up (e.g., 20→50→100→200→400 mg) under close monitoring.
   Purpose: Option in relapsed WM, often within trials or specialist centers.
   Mechanism: Blocks BCL-2, a survival protein; triggers cancer cell death.
   Side effects: Tumor lysis risk, low counts, infections, GI upset.

9. Acalabrutinib (BTK inhibitor, off-label use in WM in some regions)
   Dose/Time: 100 mg PO twice daily.
   Purpose: Alternative BTK inhibitor when others are not suitable.
   Mechanism: BTK blockade like ibrutinib/zanubrutinib.
   Side effects: Headache, low counts, infection risk; less atrial fibrillation vs ibrutinib in other diseases.

10. Cyclophosphamide (as single agent when needed)
    Dose/Time: Various oral/IV schedules (e.g., 100 mg PO daily in some palliative settings) determined by oncologist.
    Purpose: Simpler option for symptom control if combinations aren’t ideal.
    Mechanism: Alkylates DNA to stop cell division.
    Side effects: Low counts, nausea, hair thinning, bladder irritation (hydration helps).

Other agents and clinical trials: New BTK inhibitors (e.g., non-covalent options), PI3K pathway agents, CAR-T or bispecific antibodies are under study at specialized centers.

---

Dietary Molecular Supplements

Supplements are not cures for WM. They may support nutrition or symptom control. Always review supplements with your oncology team to avoid drug interactions (especially with BTK inhibitors and anticoagulants).

1. Vitamin D3 (e.g., 800–2000 IU/day; dose guided by blood level)
   Function: Bone and immune support.
   Mechanism: Modulates immune signaling; promotes calcium balance for bones.

2. Omega-3 Fatty Acids (Fish Oil) (e.g., 1–2 g/day of EPA+DHA)
   Function: Cardiometabolic support, anti-inflammatory.
   Mechanism: Alters membrane lipids and eicosanoids; may reduce triglycerides.
   Caution: May slightly increase bleeding risk with BTK inhibitors—ask your doctor.

3. Protein Supplement (Whey/Plant Protein) (as needed to meet protein goals)
   Function: Preserve muscle mass, counter fatigue.
   Mechanism: Provides essential amino acids for repair.

4. Probiotics (strain-specific; follow label; avoid if severely immunocompromised unless advised)
   Function: Gut health, stool regularity.
   Mechanism: Supports microbiome balance and gut barrier.

5. Curcumin (Turmeric Extract) (e.g., 500–1000 mg/day standardized; variable absorption)
   Function: General anti-inflammatory support.
   Mechanism: Modulates NF-κB and cytokines.
   Caution: Potential bleeding interaction; confirm with your team.

6. Magnesium (dose varies; often 200–400 mg/day)
   Function: Muscle cramps, sleep quality.
   Mechanism: Cofactor for nerve/muscle function.
   Caution: Can cause diarrhea; adjust dose.

7. B-Complex (esp. B12 if low) (dose guided by labs)
   Function: Nerve support and anemia workup if deficient.
   Mechanism: B12 is essential for red blood cell production and nerve myelin.

8. Coenzyme Q10 (e.g., 100–200 mg/day)
   Function: Mitochondrial energy support; statin-related muscle symptoms.
   Mechanism: Part of electron transport in cells.

9. Ashwagandha (dose per product; discuss first)
   Function: Stress and sleep support.
   Mechanism: Adaptogen effects on stress pathways.
   Caution: Immune-active; avoid if your team advises against.

10. Electrolyte Mix (low-sugar) (as needed for hydration)
    Function: Maintain fluid and salt balance, especially with diarrhea or hot weather.
    Mechanism: Replaces sodium/potassium to support circulation and energy.

---

Regenerative / Stem-Cell–Related” Drugs

These are supportive biologics or growth factors used by specialists. They are not anticancer cures by themselves but help immune or blood-forming systems, especially around stem cell collection or during low counts.

1. Filgrastim (G-CSF)
   Dose/Time: Commonly 5 µg/kg/day SC for several days (varies).
   Function: Boosts neutrophils (infection-fighting cells).
   Mechanism: Stimulates bone marrow to make neutrophils.

2. Pegfilgrastim (long-acting G-CSF)
   Dose/Time: 6 mg SC once per chemo cycle (typical).
   Function: Same as filgrastim but longer-lasting.
   Mechanism: Prolonged G-CSF effect.

3. Plerixafor
   Dose/Time: Dose per weight SC, used with G-CSF during stem cell mobilization.
   Function: Helps release stem cells into blood for collection before autologous transplant.
   Mechanism: CXCR4 antagonist frees stem cells from marrow niche.

4. Intravenous Immunoglobulin (IVIG)
   Dose/Time: Often 0.4 g/kg monthly for recurrent infections (varies).
   Function: Replaces antibodies in patients with low protective Ig levels.
   Mechanism: Provides pooled antibodies to fight infections.

5. Epoetin alfa (Erythropoietin)
   Dose/Time: e.g., 40,000 units SC weekly if indicated.
   Function: Helps anemia when due to low red cell production.
   Mechanism: Stimulates red blood cell formation.

6. Romiplostim or Eltrombopag (TPO receptor agonists)
   Dose/Time: Individualized dosing; weekly SC for romiplostim; daily oral for eltrombopag.
   Function: Raise platelets if severely low and other causes treated.
   Mechanism: Stimulate megakaryocytes to make platelets.

Note: These medicines are used under specialist care and are not routine for every person with WM.

---

Surgeries / Procedures

1. Therapeutic Plasma Exchange (Plasmapheresis)
   Procedure: Central or peripheral line used to filter plasma and remove IgM.
   Why Done: Emergency or urgent treatment of hyperviscosity, severe headaches, vision changes, nosebleeds.

2. Autologous Hematopoietic Stem Cell Transplant (Auto-HSCT)
   Procedure: Collect your stem cells, give high-dose chemo, then return your cells.
   Why Done: Selected, relapsed WM patients who are fit—can give long remissions.

3. Central Venous Access Device / Port Placement
   Procedure: Minor surgery to place a port under the skin for IV treatments.
   Why Done: Easier, safer infusions and blood draws during prolonged therapy.

4. Splenectomy (rare, selected cases)
   Procedure: Surgical removal of the spleen.
   Why Done: Massive symptomatic spleen enlargement with cytopenias not controlled by medicines (uncommon in WM).

5. Bone Marrow or Lymph Node Biopsy (Diagnostic)
   Procedure: Needle biopsy of marrow or node.
   Why Done: Confirm diagnosis, assess disease burden, and guide therapy.

---

Preventions

1. Keep vaccinations up to date (non-live).

2. Seek medical care promptly for fever ≥38.0°C, chills, or new cough.

3. Hydrate well, especially if IgM is high or during hot weather.

4. Avoid drugs and supplements that raise bleeding risk unless approved (e.g., NSAIDs, high-dose fish oil).

5. Use neuropathy-safe habits (foot care, safe footwear).

6. Practice fall prevention (clear pathways, night lights, handrails).

7. Maintain oral hygiene to reduce mouth infections.

8. Protect from cold exposure if you have cryoglobulin/cold agglutinin issues.

9. Keep an updated medication list and share it at every visit.

10. Maintain routine cancer follow-ups and lab checks to catch changes early.

---

When to See Doctors Urgently

• Sudden headaches, vision changes, nosebleeds, confusion, chest pain, or shortness of breath (possible hyperviscosity or clot/bleeding).

• Fever ≥38.0°C (100.4°F), shaking chills, or fast-worsening cough (possible serious infection).

• Black tarry stools, vomiting blood, heavy bruising or bleeding.

• New severe numbness/weakness, trouble walking, or sudden back pain (nerve or spinal issues).

• Rapid swelling of lymph nodes or abdomen, or very fast fatigue decline.

---

What to Eat and What to Avoid

What to Eat

• Lean proteins (fish, poultry, eggs, tofu, legumes) to maintain muscle.

• Colorful fruits and vegetables for vitamins, minerals, and antioxidants.

• Whole grains (brown rice, oats, whole-wheat) for steady energy.

• Healthy fats (olive oil, nuts, seeds, avocado) for heart and brain health.

• Plenty of fluids (water, broths, low-sugar electrolyte drinks) to support circulation.

• Calcium and vitamin D sources (dairy or fortified plant milks, leafy greens) for bone health.

What to Avoid or Limit

• Alcohol excess (can worsen bleeding and interact with drugs).

• High-salt processed foods (can worsen blood pressure and swelling).

• Grapefruit or Seville orange products with certain drugs (interactions—ask your team).

• Very raw or unpasteurized foods if counts are very low (infection risk).

• Mega-dose supplements that raise bleeding risk (high-dose fish oil, ginkgo) without approval.

• Energy drinks and excess caffeine if you have heart-rhythm concerns.

---

Frequently Asked Questions (FAQs)

1. Is WM curable?
   WM is usually not considered curable, but it is often very treatable. Many people live for years with good quality of life using periodic treatments.

2. Do all patients need immediate treatment?
   No. If you have no symptoms and labs are stable, a watch-and-wait approach is safe. Start treatment when symptoms or complications appear.

3. What triggers urgent treatment?
   Hyperviscosity symptoms, severe anemia, repeated infections, kidney issues from IgM, significant neuropathy, cryoglobulinemia, or organ enlargement that causes problems.

4. Why does rituximab sometimes raise IgM at first?
   It can cause an “IgM flare”—a temporary increase. Doctors may use plasmapheresis around treatment to prevent complications if your baseline IgM is very high.

5. What are BTK inhibitors and why are they important?
   They are pills that block Bruton’s tyrosine kinase, a key survival signal for WM cells. They have changed WM care because many patients respond well and can take them long-term.

6. Which BTK inhibitor is “best”?
   Your doctor chooses based on your heart health, other illnesses, drug interactions, and local approvals. Zanubrutinib is often favored for its balance of efficacy and safety; others (ibrutinib, acalabrutinib) are also used based on circumstances.

7. Will I lose my hair?
   Many WM regimens cause less hair loss than classic chemotherapy. Hair loss risk depends on the drugs used.

8. Can WM cause nerve problems?
   Yes. IgM can attack nerves (anti-MAG neuropathy), and some medicines can worsen neuropathy. Your team will tailor drugs and schedules to protect nerves.

9. How often will I need blood tests?
   During watchful waiting, typically every 3–6 months. During treatment, labs are more frequent (often before each cycle or monthly with BTK inhibitors).

10. Can I travel?
    Yes—plan ahead. Carry medication lists, get travel insurance, stay hydrated, and move legs on long trips to reduce clot risk.

11. Can diet or supplements treat WM?
    No. They support overall health but do not replace medical treatment. Always check for interactions.

12. Is stem cell transplant common in WM?
    It’s selective—used for fit patients with relapsed disease at specialized centers. It is not routine for everyone.

13. Will treatment affect my heart?
    Some medicines (e.g., ibrutinib) can affect heart rhythm or blood pressure. Your team will monitor and may choose alternatives if you have heart disease.

14. What if I’m bleeding or bruising easily?
    Tell your team promptly. Platelets may be low or a drug may raise bleeding risk. You may need dose changes or added precautions.

15. Are clinical trials worth considering?
    Yes. Trials offer access to new therapies and expert care. Ask your oncologist about options at academic centers.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 30, 2025.